ACSM[042-082]

58 GUIDELINES FOR EXERCISE TESTING • www.acsm.org
response to exercise and significantly reduce the sensitivity of ECG changes
for ischemia. Patients taking intermediate- or high-dose -blocking agents
may be asked to taper their medication over a two- to four-day period to minimize
hyperadrenergic withdrawal responses.
• If the test is for functional or exercise prescription purposes, patients should
continue their medication regimen on their usual schedule so that the exercise
responses will be consistent with responses expected during exercise
training.
• Participants should bring a list of their medications, including dosage and frequency
of administration, to the assessment and should report the last actual
dose taken. As an alternative, participants may wish to bring their medications
with them for the exercise testing staff to record.
• Drink ample fluids over the 24-hour period preceding the test to ensure normal
hydration before testing.
REFERENCES
1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients
with ST-elevation myocardial infarction. Circulation. 2004;110:282–92.
2. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific
statement from the American Heart Association. Circulation. 2006;47:296–308.
3. Bickley LS. Bate’s pocket guide to physical examination and history taking. 4th ed. Philadelphia
(PA): Lippincott Williams & Wilkins; 2003.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management
of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association task force on practice guidelines
[Internet]. 2002 [cited 2007 June 15]. Available from: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf
5. Ferguson GT, Enright PL, Buist AS, et al. Office spirometry for lung health assessment in adults: a
consensus statement from the National Lung Health Education Program. Chest. 2000;117:
1146–61.
6. Fuster V, Pearson TA. 27th Bethesda Conference: Matching the intensity of risk factor management
with the hazard for coronary disease events. September 14–15, 1995. J Am Coll Cardiol.
1996;27:957–1047.
7. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 Guideline Update for Exercise Testing; a
report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines; Committee on Exercise Testing, 2002. Circulation. 2002;106(14):1883–92.
8. Grundy SM, Cleeman JI, Bairey Merz NC, et al. Implications of recent clinical trials for the National
Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol.
2004;44:720–32.
9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. ATS/ERS Task Force: standardisation
of lung function testing. Eur Respir J. 2005;26:319–38.
10. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). Washington, DC:2002. NIH Publication No. 02-5215.
11. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Washington,
DC:2003; 03-5233.
12. Pauwels RA, Buist AS, Calverly PM, et al. Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic
Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med [Internet]. 2001
[cited 2007 June 15];163:1256–76. Available from: http//www.goldcopd.com (last major revision,
November 2006).